Literature DB >> 26717952

Irritable Bowel Syndrome: A Clinical Review.

Michael D Cashman1, Daniel K Martin, Sonu Dhillon, Srinivas R Puli.   

Abstract

Symptoms of irritable bowel syndrome (IBS) are common in population studies including chronic abdominal pain associated with altered bowel habits. Patients often have associated gastrointestinal and somatic symptoms suggesting a possible common contributing mechanism, but the heterogeneous symptom patterns of individual patients make generalizations difficult. The pathophysiology of IBS is incompletely understood but includes disturbances of the brain-gut axis. Central mechanisms are: the psychosocial history and environment, dysfunctional brain processing of peripheral signals attributed to the intestine including the enteric nervous system, the microbiome and the innate and adaptive immune system. As a result there is visceral hypersensitivity and disturbed intestinal secretory and motor activity. Some mechanisms of visceral pain hypersensitivity may overlap with other pain syndromes including fibromyalgia (FMS). Central Sensitization (CS) would offer a way to conceptualize an integration of life experience and psychologic response into a biopsychosocial framework of pathophysiology, diagnosis and treatment of IBS. Corticotropin-releasing factor, a principle regulator in the stress and pain response may contribute to a neuroendocrine mechanism for the brain-gut interaction. The positive diagnostic approach to IBS symptoms to avoid excess testing and enhance the patient-provider therapeutic relationship requires the recognition of the "cluster" of IBS symptoms while identifying "alarm" symptoms requiring specific attention. The severity of the symptoms and other individual psychosocial factors characterize patients who seek medical care. The presence of significant psychosocial comorbidities adds to the complexity of management which often requires a multidisciplinary approach. Several treatment options exist but no single method is effective for all the symptoms of IBS. The therapeutic benefit of the well-executed physician-patient relationship is considered essential to success in managing IBS symptoms over the long term.

Entities:  

Mesh:

Year:  2016        PMID: 26717952     DOI: 10.2174/1573397112666151231110521

Source DB:  PubMed          Journal:  Curr Rheumatol Rev        ISSN: 1573-3971


  11 in total

1.  Opposing Roles of Estradiol and Testosterone on Stress-Induced Visceral Hypersensitivity in Rats.

Authors:  Yaping Ji; Bo Hu; Jiyun Li; Richard J Traub
Journal:  J Pain       Date:  2018-03-02       Impact factor: 5.820

2.  Neuronal Nitric Oxide Synthase Is a Novel Biomarker for the Interstitial Cells of Cajal in Stress-Induced Diarrhea-Dominant Irritable Bowel Syndrome.

Authors:  Da Eun Jang; Ji Hyun Bae; Yoo Jin Chang; Yoon Hoo Lee; Ki Taek Nam; Il Yong Kim; Je Kyung Seong; Yong Chan Lee; Su Cheong Yeom
Journal:  Dig Dis Sci       Date:  2018-01-25       Impact factor: 3.199

3.  Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; David L Stevens; Essie Komla; Dana E Selley; William L Dewey; Hamid I Akbarali; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2018-07-23       Impact factor: 4.418

4.  Intestinal Dysmotility Syndromes following Systemic Infection by Flaviviruses.

Authors:  James P White; Shanshan Xiong; Nicole P Malvin; William Khoury-Hanold; Robert O Heuckeroth; Thaddeus S Stappenbeck; Michael S Diamond
Journal:  Cell       Date:  2018-10-04       Impact factor: 41.582

5.  Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.

Authors:  Anca Trifan; Ovidiu Burta; Nicoleta Tiuca; Diana Corina Petrisor; Augustin Lenghel; Javier Santos
Journal:  United European Gastroenterol J       Date:  2019-07-03       Impact factor: 4.623

6.  Effects of Vitamin D Supplementation in Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  Mahsa Jalili; Homayoon Vahedi; Hossein Poustchi; Azita Hekmatdoost
Journal:  Int J Prev Med       Date:  2019-02-12

7.  Multi-omics Analysis of Gut Microbiota and Metabolites in Rats With Irritable Bowel Syndrome.

Authors:  Si Liu; Chaozeng Si; Yang Yu; Guiping Zhao; Lei Chen; Yu Zhao; Zheng Zhang; Hengcun Li; Yang Chen; Li Min; Shutian Zhang; Shengtao Zhu
Journal:  Front Cell Infect Microbiol       Date:  2019-05-29       Impact factor: 5.293

8.  Long-term effect of moxibustion on irritable bowel syndrome with diarrhea: a randomized clinical trial.

Authors:  Chunhui Bao; Luyi Wu; Yin Shi; Zheng Shi; Xiaoming Jin; Jiacheng Shen; Jing Li; Zhihai Hu; Jianhua Chen; Xiaoqing Zeng; Wei Zhang; Zhe Ma; Zhijun Weng; Jinmei Li; Huirong Liu; Huangan Wu
Journal:  Therap Adv Gastroenterol       Date:  2022-02-23       Impact factor: 4.409

9.  Eph/ephrin signalling serves a bidirectional role in lipopolysaccharide‑induced intestinal injury.

Authors:  Ying Xiong; Kai-Xue Li; Hong Wei; Lu Jiao; Shao-Yong Yu; Li Zeng
Journal:  Mol Med Rep       Date:  2018-06-14       Impact factor: 2.952

10.  Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT.

Authors:  Vladimir T Ivashkin; Elena A Poluektova; Alexey B Glazunov; Mikhail A Putilovskiy; Oleg I Epstein
Journal:  BMC Gastroenterol       Date:  2019-12-31       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.